Total Payments
$55,199
2024 Payments
$405.40
Companies
6
Transactions
41
Medicare Patients
2,286
Medicare Billing
$300,019
Payment Breakdown by Category
Other$43,369 (78.6%)
Research$11,188 (20.3%)
Food & Beverage$620.12 (1.1%)
Education$22.36 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,369 | 31 | 73.1% |
| Unspecified | $11,188 | 4 | 20.3% |
| Honoraria | $3,000 | 1 | 5.4% |
| Food and Beverage | $620.12 | 4 | 1.1% |
| Education | $22.36 | 1 | 0.0% |
Payments by Type
General
$44,012
37 transactions
Research
$11,188
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $39,265 | 17 | $0 (2023) |
| Eli Lilly and Company | $11,188 | 4 | $0 (2021) |
| PFIZER INC. | $3,000 | 1 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,342 | 17 | $0 (2022) |
| ERBE USA INC | $265.00 | 1 | $0 (2024) |
| Celltrion USA Inc. | $140.40 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $405.40 | 2 | ERBE USA INC ($265.00) |
| 2023 | $214.72 | 2 | AbbVie Inc. ($214.72) |
| 2022 | $22.36 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($22.36) |
| 2021 | $13,532 | 4 | Eli Lilly and Company ($10,532) |
| 2019 | $139.69 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($139.69) |
| 2018 | $20,760 | 14 | AbbVie, Inc. ($19,800) |
| 2017 | $20,125 | 15 | AbbVie, Inc. ($19,250) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/03/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $140.40 | General |
| Category: ONCOLOGY | ||||||
| 04/16/2024 | ERBE USA INC | VIO3 (Device) | Food and Beverage | Cash or cash equivalent | $265.00 | General |
| Category: Gastroenterology | ||||||
| 12/15/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $94.61 | General |
| 12/13/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $120.11 | General |
| Category: IMMUNOLOGY | ||||||
| 06/23/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Education | In-kind items and services | $22.36 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/25/2021 | PFIZER INC. | XELJANZ (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/10/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $895.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | ||||||
| 04/27/2021 | Eli Lilly and Company | — | — | In-kind items and services | $265.78 | Research |
| Study: A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | ||||||
| 04/01/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $9,371.70 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | ||||||
| 02/13/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $124.94 | General |
| Category: Lower GI | ||||||
| 02/13/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $11.98 | General |
| Category: Lower GI | ||||||
| 02/13/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2.77 | General |
| Category: Lower GI | ||||||
| 11/12/2018 | AbbVie, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| 11/06/2018 | AbbVie, Inc. | Humira (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Immunology | ||||||
| 10/25/2018 | Eli Lilly and Company | — | — | In-kind items and services | $655.13 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | ||||||
| 08/02/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $236.91 | General |
| Category: Lower GI | ||||||
| 07/23/2018 | AbbVie, Inc. | Humira (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Immunology | ||||||
| 07/17/2018 | AbbVie, Inc. | Humira (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Immunology | ||||||
| 06/15/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $40.80 | General |
| Category: Lower GI | ||||||
| 06/04/2018 | AbbVie, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| 05/23/2018 | AbbVie, Inc. | Humira (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Immunology | ||||||
| 05/17/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3.98 | General |
| Category: Lower GI | ||||||
| 04/16/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $19.44 | General |
| Category: Lower GI | ||||||
| 03/26/2018 | AbbVie, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| 03/05/2018 | AbbVie, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $9,372 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $1,550 | 2 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $265.78 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 616 | 699 | $706,733 | $78,145 |
| 2022 | 11 | 559 | 645 | $629,359 | $73,447 |
| 2021 | 12 | 639 | 730 | $666,477 | $87,580 |
| 2020 | 13 | 472 | 554 | $466,775 | $60,848 |
Total Patients
2,286
Total Services
2,628
Medicare Billing
$300,019
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 129 | $88,881 | $14,434 | 16.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 49 | 49 | $133,231 | $10,975 | 8.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 81 | 82 | $49,610 | $9,790 | 19.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 82 | 119 | $38,318 | $8,657 | 22.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $43,099 | $6,866 | 15.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 96 | $47,424 | $6,582 | 13.9% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 39 | 39 | $79,677 | $6,496 | 8.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 42 | 42 | $101,766 | $6,048 | 5.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 35 | 35 | $62,860 | $3,270 | 5.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 36 | 36 | $22,392 | $2,941 | 13.1% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 25 | 25 | $39,475 | $2,085 | 5.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 91 | 112 | $77,168 | $12,821 | 16.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 79 | 79 | $47,795 | $10,051 | 21.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 91 | 135 | $43,470 | $8,885 | 20.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 37 | 37 | $100,603 | $8,542 | 8.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 43 | 43 | $104,189 | $7,203 | 6.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 50 | 50 | $45,850 | $7,033 | 15.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 61 | 77 | $38,038 | $6,348 | 16.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 24 | 25 | $51,075 | $4,116 | 8.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 37 | 40 | $71,840 | $4,081 | 5.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 26 | 26 | $16,172 | $2,427 | 15.0% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 20 | 21 | $33,159 | $1,941 | 5.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 103 | 134 | $63,650 | $15,032 | 23.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 94 | 94 | $56,870 | $12,197 | 21.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 70 | 70 | $51,520 | $10,128 | 19.7% |
About Dr. Keith Sultan, MD
Dr. Keith Sultan, MD is a Gastroenterology healthcare provider based in Manhasset, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083713010.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Keith Sultan, MD has received a total of $55,199 in payments from pharmaceutical and medical device companies, with $405.40 received in 2024. These payments were reported across 41 transactions from 6 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($40,369).
As a Medicare-enrolled provider, Sultan has provided services to 2,286 Medicare beneficiaries, totaling 2,628 services with total Medicare billing of $300,019. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Manhasset, NY
- Active Since 09/22/2006
- Last Updated 07/19/2012
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1083713010
Products in Payments
- Humira (Biological) $26,400
- XELJANZ (Drug) $3,000
- Entyvio (Biological) $1,319
- VIO3 (Device) $265.00
- VEGZELMA (Biological) $140.40
- SKYRIZI (Biological) $120.11
- ENTYVIO (Biological) $22.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Manhasset
David Bernstein, Md, MD
Gastroenterology — Payments: $359,870
Gastroenterology $359,870
Dr. Calvin Lee, M.d, M.D
Gastroenterology — Payments: $1,152
Gastroenterology $1,152
Dr. Susan Ramdhaney, M.d, M.D
Gastroenterology — Payments: $908.59
Gastroenterology $908.59
Bernard Stark, Md, MD
Gastroenterology — Payments: $745.37
Gastroenterology $745.37
Edna Khodadadian, Md, MD
Gastroenterology — Payments: $716.43
Gastroenterology $716.43
Chun Kit Hung, Md, MD
Gastroenterology — Payments: $617.11
Gastroenterology $617.11